thewayne: (Default)
[personal profile] thewayne
The bill passed the Commons 314-291 and now goes to the Lords, and I don't have a clue what happens there.

The bill is fairly simple in operation. If you have a terminal condition and six months to live, you have the right to end your life. Two doctors go before a three-person panel who must approve your application, and that seems to about it. The original legislation had the two doctors going before a judge, fears of further clogging up the judiciary had them change it to the panel. No information on how the panel is constituted.

Canada, Spain, New Zealand, most of Australia, and clinics in Switzerland support assisted dying, along with the USA states Oregon, Washington, and California.

https://edition.cnn.com/2025/06/20/uk/uk-assisted-dying-commons-vote-gbr-intl

https://news.slashdot.org/story/25/06/20/1354239/lawmakers-in-britain-narrowly-approve-bill-to-legalize-assisted-dying
thewayne: (Default)
[personal profile] thewayne
Scammers have found an interesting trick via Google ads, and thus far it only seems to work with them, no other online ad company. They buy an ad, for example, for Microsoft.com, that says 'Call us toll free at 805-xxx-xxxx' and it pops up as a banner at the top of the page!

So you're browsing for whatever, and this page pops up and the URL looks completely legit, and there's a phone number just below the top of the page, do you trust it?

Well, looks like these days you shouldn't.

Might want to spread the word, and article, to your more gullible friends and older relations.

https://arstechnica.com/security/2025/06/tech-support-scammers-inject-malicious-phone-numbers-into-big-name-websites/
thewayne: (Default)
[personal profile] thewayne
The European Union, on top of France's recruiting efforts, is investing €500 million to lure displaced/disaffected American scientists to the other side of the pond. France has a head-start, having begun their program pretty much as soon as the Ketamine Kid and his goon squad started axing programs. The EU amount is about $570m USD, I'm not sure how many jobs that represents. What they need to do is relax visa restrictions to allow people to move without having direct job sponsorship: give them longer to find employment if they can't fall in directly to their recruitment program.

This paragraph makes me wonder if this program replaces the French program:
"The plan, originally proposed by the French government, also proposes creating long-term “super grants” for outstanding researchers, to provide them with financial stability; these would last for seven years. The program also plans to double the amount of financial support available this year for those who decide to move to the European Union."

I'm not really clear on the matter. But since they're not likely to be looking for telescope operators, we're not likely to fall into this program.

https://arstechnica.com/science/2025/05/europe-launches-program-to-lure-scientists-away-from-the-us/


Japan's program is throwing a cool ¥100 billion ($693 million) into the program. Meanwhile, Great Britain is throwing a whopping £50 million ($67 million) to attract top talent!

I can see Japan increasing their spend as they have a serious population problem: a shortage of young families with children. By bringing in more scientists, they may well give extra priority to those that might shore up that base, giving long-term benefit to the country.

https://www.theregister.com/2025/06/16/japan_has_a_yen_for/
thewayne: (Default)
[personal profile] thewayne
That's $450.00, as in I can pull that out of an ATM pretty much any time. Not $450 million. A little under five hundred bucks, and they lost their lock on their second largest market.

The Slashdot summary says it best:
"Pharmaceutical giant Novo Nordisk forfeited patent protection for semaglutide -- the active ingredient in blockbuster diabetes and weight loss drugs Ozempic and Wegovy -- in Canada after failing to pay a $450 maintenance fee in 2019. The company had paid maintenance fees through 2018 but requested a refund for the 2017 fee, apparently seeking more time to decide whether to continue protecting the patent.

When the 2019 fee came due at $450 with late penalties, Novo never paid despite having a one-year grace period. Canadian patent authorities confirmed the patent "cannot be revived" once lapsed. The oversight is particularly costly given Canada represents the world's second-largest semaglutide market, worth billions annually. Generic drugmaker Sandoz plans to launch a competing version in early 2026, while Novo's U.S. patent protection extends until at least 2032.


WOW. That's certainly going to tarnish some board member's CV. But it's going to make a bunch of Canadian's a lot thinner!

https://www.science.org/content/blog-post/novo-nordisk-s-canadian-mistake

https://science.slashdot.org/story/25/06/16/1438211/novo-nordisk-loses-canadian-patent-protection-for-blockbuster-diabetes-drug-over-unpaid-450-fee
Page generated Jun. 27th, 2025 06:52 pm
Powered by Dreamwidth Studios